Literature DB >> 21658962

Synthesis and radiolabeling of chelator-RNA aptamer bioconjugates with copper-64 for targeted molecular imaging.

William M Rockey1, Ling Huang, Kyle C Kloepping, Nicholas J Baumhover, Paloma H Giangrande, Michael K Schultz.   

Abstract

Ribonucleic acid (RNA) aptamers with high affinity and specificity for cancer-specific cell-surface antigens are promising reagents for targeted molecular imaging of cancer using positron emission tomography (PET). For this application, aptamers must be conjugated to chelators capable of coordinating PET-radionuclides (e.g., copper-64, (64)Cu) to enable radiolabeling for in vivo imaging of tumors. This study investigates the choice of chelator and radiolabeling parameters such as pH and temperature for the development of (64)Cu-labeled RNA-based targeted agents for PET imaging. The characterization and optimization of labeling conditions are described for four chelator-aptamer complexes. Three commercially available bifunctional macrocyclic chelators (1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid mono N-hydroxysuccinimide [DOTA-NHS]; S-2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid [p-SCN-Bn-NOTA]; and p-SCN-Bn-3,6,9,15-tetraazabicyclo [9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triacetic acid [p-SCN-Bn-PCTA]), as well as the polyamino-macrocyclic diAmSar (3,6,10,13,16,19-hexaazabicyclo[6.6.6] icosane-1,8-diamine) were conjugated to A10-3.2, a RNA aptamer which has been shown to bind specifically to a prostate cancer-specific cell-surface antigen (PSMA). Although a commercial bifunctional version of diAmSar was not available, RNA conjugation with this chelator was achieved in a two-step reaction by the addition of a disuccinimidyl suberate linker. Radiolabeling parameters (e.g., pH, temperature, and time) for each chelator-RNA conjugate were assessed in order to optimize specific activity and RNA stability. Furthermore, the radiolabeled chelator-coupled RNA aptamers were evaluated for binding specificity to their target antigen. In summary, key parameters were established for optimal radiolabeling of RNA aptamers for eventual PET imaging with (64)Cu.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21658962      PMCID: PMC4083585          DOI: 10.1016/j.bmc.2011.05.010

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  35 in total

1.  Copper-64-pyruvaldehyde-bis(N(4)-methylthiosemicarbazone) for the prevention of tumor growth at wound sites following laparoscopic surgery: monitoring therapy response with microPET and magnetic resonance imaging.

Authors:  Jason S Lewis; Judith M Connett; Joel R Garbow; Thomas L Buettner; Yasuhisa Fujibayashi; James W Fleshman; Michael J Welch
Journal:  Cancer Res       Date:  2002-01-15       Impact factor: 12.701

2.  Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities.

Authors:  Wouter A P Breeman; Marion De Jong; Theo J Visser; Jack L Erion; Eric P Krenning
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-04-04       Impact factor: 9.236

3.  Tenascin-C aptamers are generated using tumor cells and purified protein.

Authors:  B J Hicke; C Marion; Y F Chang; T Gould; C K Lynott; D Parma; P G Schmidt; S Warren
Journal:  J Biol Chem       Date:  2001-10-04       Impact factor: 5.157

4.  Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands.

Authors:  Xiankai Sun; Melinda Wuest; Gary R Weisman; Edward H Wong; David P Reed; C Andrew Boswell; Ramunas Motekaitis; Arthur E Martell; Michael J Welch; Carolyn J Anderson
Journal:  J Med Chem       Date:  2002-01-17       Impact factor: 7.446

5.  In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver.

Authors:  L A Bass; M Wang; M J Welch; C J Anderson
Journal:  Bioconjug Chem       Date:  2000 Jul-Aug       Impact factor: 4.774

6.  Microwave-supported preparation of (68)Ga bioconjugates with high specific radioactivity.

Authors:  I Velikyan; G J Beyer; B Långström
Journal:  Bioconjug Chem       Date:  2004 May-Jun       Impact factor: 4.774

7.  A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment.

Authors:  Dion A Daniels; Hang Chen; Brian J Hicke; Kristine M Swiderek; Larry Gold
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-15       Impact factor: 11.205

8.  Peptide receptor radionuclide therapy in vitro using [111In-DTPA0]octreotide.

Authors:  Astrid Capello; Eric P Krenning; Wout A P Breeman; Bert F Bernard; Marion de Jong
Journal:  J Nucl Med       Date:  2003-01       Impact factor: 10.057

9.  Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes.

Authors:  C Andrew Boswell; Xiankai Sun; Weijun Niu; Gary R Weisman; Edward H Wong; Arnold L Rheingold; Carolyn J Anderson
Journal:  J Med Chem       Date:  2004-03-11       Impact factor: 7.446

10.  68Ga-labeled oligonucleotides for in vivo imaging with PET.

Authors:  Anne Roivainen; Tuula Tolvanen; Satu Salomäki; Gabor Lendvai; Irina Velikyan; Petri Numminen; Maria Välilä; Hannu Sipilä; Mats Bergström; Pirkko Härkönen; Harri Lönnberg; Bengt Långström
Journal:  J Nucl Med       Date:  2004-02       Impact factor: 10.057

View more
  30 in total

1.  2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.

Authors:  Ying Chen; Mrudula Pullambhatla; Catherine A Foss; Youngjoo Byun; Sridhar Nimmagadda; Srinivasan Senthamizhchelvan; George Sgouros; Ronnie C Mease; Martin G Pomper
Journal:  Clin Cancer Res       Date:  2011-10-31       Impact factor: 12.531

Review 2.  GCPII imaging and cancer.

Authors:  C A Foss; R C Mease; S Y Cho; H J Kim; M G Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 3.  Molecular imaging with nucleic acid aptamers.

Authors:  H Hong; S Goel; Y Zhang; W Cai
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 4.  Recent developments in protein and cell-targeted aptamer selection and applications.

Authors:  Jun Liu; Mingxu You; Ying Pu; Huixia Liu; Mao Ye; Weihong Tan
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 5.  The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research.

Authors:  Benjamin T Ristau; Denise S O'Keefe; Dean J Bacich
Journal:  Urol Oncol       Date:  2013-12-08       Impact factor: 3.498

Review 6.  Improving external beam radiotherapy by combination with internal irradiation.

Authors:  A Dietrich; L Koi; K Zöphel; W Sihver; J Kotzerke; M Baumann; M Krause
Journal:  Br J Radiol       Date:  2015-03-18       Impact factor: 3.039

Review 7.  The role of nuclear medicine in modern therapy of cancer.

Authors:  Gabriela Kramer-Marek; Jacek Capala
Journal:  Tumour Biol       Date:  2012-03-24

Review 8.  PET imaging in prostate cancer: focus on prostate-specific membrane antigen.

Authors:  Ronnie C Mease; Catherine A Foss; Martin G Pomper
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

Review 9.  Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer.

Authors:  C Bařinka; C Rojas; B Slusher; M Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

10.  "Click"-cyclized (68)Ga-labeled peptides for molecular imaging and therapy: synthesis and preliminary in vitro and in vivo evaluation in a melanoma model system.

Authors:  Molly E Martin; M Sue O'Dorisio; Whitney M Leverich; Kyle C Kloepping; Susan A Walsh; Michael K Schultz
Journal:  Recent Results Cancer Res       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.